PULSE PVC Registry: Multicenter Study on Focal Pulsed Field Ablation for Premature Ventricular Contractions
Launched by ZENTRALKLINIK BAD BERKA · May 25, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The PULSE PVC Registry is a European multicenter observational registry designed to evaluate the safety, feasibility, and midterm outcomes of focal pulsed field ablation (PFA) for the treatment of symptomatic premature ventricular contractions (PVCs). The study includes patients undergoing focal PFA using a monopolar biphasic energy system (Centauri Generator), across multiple high-volume electrophysiology centers in Europe.
The registry collects detailed baseline demographics, comorbidities (e.g., hypertension, diabetes, chronic kidney disease), structural heart disease status, antiarrhyt...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with symptomatic PVCs who underwent focal monopolar biphasic PFA
- • Use of Centauri Generator system
- • Minimum 3-month clinical follow-up at time of data entry
- Exclusion Criteria:
- • Incomplete procedural or follow-up data
- • Patients receiving exclusively RF ablation
About Zentralklinik Bad Berka
Zentralklinik Bad Berka is a leading healthcare institution in Germany, renowned for its commitment to high-quality patient care and advanced medical research. With a focus on innovative treatment approaches and comprehensive clinical services, the clinic specializes in various medical fields, including rehabilitation and specialized care for chronic conditions. As a dedicated clinical trial sponsor, Zentralklinik Bad Berka actively participates in the development of new therapies and medical technologies, collaborating with academic institutions and industry partners to enhance patient outcomes and contribute to the advancement of medical science. Their rigorous adherence to ethical standards and regulatory compliance underscores their mission to improve healthcare delivery through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Berka, , Germany
Bad Berka, Thüringen, Germany
Patients applied
Trial Officials
J. Christoph Geller, Prof. Dr.
Study Director
Zentralklinikum Bad berka
Santi Raffa, Dr.
Study Director
Zentralklinik Bad Berka
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported